Login / Signup

Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease.

Jongyoon ShinnJuyeon LeeSeon Ah LeeSeon Ju LeeAh Hyun ChoiJung Seo KimSu Jin KimHyo Jin KimCherin LeeYejin KimJoohyeon KimJonghee ChoiByungchae JungTaeho KimHyeonTaek NamHyungjun KimYonghyun Lee
Published in: Pharmaceutics (2022)
RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.
Keyphrases
  • cancer therapy
  • hyaluronic acid
  • drug delivery
  • ulcerative colitis
  • risk assessment
  • combination therapy
  • replacement therapy